[go: up one dir, main page]

WO2004042064A3 - Troubles du metabolisme des lipides - Google Patents

Troubles du metabolisme des lipides Download PDF

Info

Publication number
WO2004042064A3
WO2004042064A3 PCT/GB2003/004816 GB0304816W WO2004042064A3 WO 2004042064 A3 WO2004042064 A3 WO 2004042064A3 GB 0304816 W GB0304816 W GB 0304816W WO 2004042064 A3 WO2004042064 A3 WO 2004042064A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
lipid metabolism
disease
cmrd
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/004816
Other languages
English (en)
Other versions
WO2004042064A2 (fr
Inventor
James Scott
Carol Christine Shoulders
Paul Simon Freemont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0226039A external-priority patent/GB0226039D0/en
Priority claimed from GB0226152A external-priority patent/GB0226152D0/en
Priority claimed from GB0305463A external-priority patent/GB0305463D0/en
Priority claimed from GB0323689A external-priority patent/GB0323689D0/en
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Priority to AU2003279461A priority Critical patent/AU2003279461A1/en
Publication of WO2004042064A2 publication Critical patent/WO2004042064A2/fr
Publication of WO2004042064A3 publication Critical patent/WO2004042064A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des molécules d'acide nucléique isolées ou recombinantes présentant une ou plusieurs mutations liées à des troubles du métabolisme des lipides, tels que la maladie de retenue des chylomicrons (CMRD), la maladie d'Andersen (AD), la maladie de retenue des chylomicrons associée au syndrome de Marinesco-Sjogren (CMRD associé à MSS), l'obésité, la résistance à l'insuline, le diabète de type II, l'athérosclérose, la dyslipidémie, et l'hyperlipidémie. Elle concerne également les polypeptides codés par ces molécules d'acide nucléique ayant subi une mutation. Elle concerne également le diagnostic, la prophylaxie et/ou le traitement de maladies du métabolisme des lipides.
PCT/GB2003/004816 2002-11-07 2003-11-07 Troubles du metabolisme des lipides Ceased WO2004042064A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003279461A AU2003279461A1 (en) 2002-11-07 2003-11-07 Disorders of lipid metabolism

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0226039A GB0226039D0 (en) 2002-11-07 2002-11-07 Conditions of lipid excess
GB0226039.6 2002-11-07
GB0226152A GB0226152D0 (en) 2002-11-08 2002-11-08 Conditions of lipid excess
GB0226152.7 2002-11-08
GB0305463.2 2003-03-10
GB0305463A GB0305463D0 (en) 2003-03-10 2003-03-10 Disorders of lipid metabolism
GB0323689.0 2003-10-09
GB0323689A GB0323689D0 (en) 2003-10-09 2003-10-09 Disorders of lipid metabolism

Publications (2)

Publication Number Publication Date
WO2004042064A2 WO2004042064A2 (fr) 2004-05-21
WO2004042064A3 true WO2004042064A3 (fr) 2004-12-02

Family

ID=32314923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/004816 Ceased WO2004042064A2 (fr) 2002-11-07 2003-11-07 Troubles du metabolisme des lipides

Country Status (2)

Country Link
AU (1) AU2003279461A1 (fr)
WO (1) WO2004042064A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217657A (zh) * 2016-05-27 2023-06-06 辛赛克斯公司 蛋白质界面

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DANNOURA A H ET AL: "Anderson's disease: exclusion of apolipoprotein and intracellular lipid transport genes.", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY. OCT 1999, vol. 19, no. 10, October 1999 (1999-10-01), pages 2494 - 2508, XP002292952, ISSN: 1079-5642 *
ESPENSHADE PETER J ET AL: "Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 18, 3 September 2002 (2002-09-03), pages 11694 - 11699, XP002293708, ISSN: 0027-8424 *
HUSSAIN M M: "A proposed model for the assembly of chylomicrons.", ATHEROSCLEROSIS. JAN 2000, vol. 148, no. 1, January 2000 (2000-01-01), pages 1 - 15, XP002292733, ISSN: 0021-9150 *
JONES BETHAN ET AL: "Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders.", NATURE GENETICS. MAY 2003, vol. 34, no. 1, May 2003 (2003-05-01), pages 29 - 31, XP002292736, ISSN: 1061-4036 *
KUGE OSAMU ET AL: "Sar1 promotes vesicle budding from the endoplasmic reticulum but not Golgi compartments", JOURNAL OF CELL BIOLOGY, vol. 125, no. 1, 1994, pages 51 - 65, XP002292735, ISSN: 0021-9525 *
SHOULDERS CAROL C ET AL: "The intracellular transport of chylomicrons requires the small GTPase, Sar1b.", CURRENT OPINION IN LIPIDOLOGY. APR 2004, vol. 15, no. 2, April 2004 (2004-04-01), pages 191 - 197, XP002292737, ISSN: 0957-9672 *

Also Published As

Publication number Publication date
WO2004042064A2 (fr) 2004-05-21
AU2003279461A1 (en) 2004-06-07
AU2003279461A8 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
WO2003059934A3 (fr) Proteines de fusion d'albumine
EP1435957A4 (fr) Inhibiteurs de gsk-3 et structures cristallines de la proteine gsk-3beta et de complexes proteiques
TNSN08064A1 (en) Albumin fusion proteins
WO2009149171A3 (fr) Mutants fgf21 et leurs utilisations
WO2010042747A3 (fr) Mutants fgf21 et leurs utilisations
WO2001079442A3 (fr) Proteines fusionnees a de l'albumine
EP2287165A3 (fr) Dérivés d'hétéroaryle et aryle fusionné en tant que modulateurs du métabolisme et prophylaxie et traitement des troubles associés
ATE444307T1 (de) Muteine des fibroblasten-wachstumsfaktors 21
WO2006024547A3 (fr) Utilisation de peptides obtenus par mutations systematiques d'aminoacides simples de la sequence a humaine ou non-humaine de la hmgb 1 pour prevenir et/ou antagoniser des pathologies induites par la hmgb 1
IL186772A0 (en) Glp-1 pegylated compounds
WO2003075858A3 (fr) Heterocycles bicycliques pour le traitement des diabetes et d'autres maladies
WO2001021589A3 (fr) Mono-indolylquinones et bi-indolyquinones et usage therapeutique et prophylactique de celles-ci
PT1151102E (pt) Composicoes de leptina glicosilada e metodos afins
US20110294729A1 (en) Novel Insulin Analogues
EA200800548A1 (ru) Гибридные полипептиды с селектируемыми свойствами
WO2003024991A3 (fr) Molecules receptrices de ligand tall-1, et utilisations correspondantes
WO2004003144A3 (fr) Anticorps qui se lient specifiquement a reg iv
WO2006052821A3 (fr) Compositions et procedes de traitement de pliage errone de proteines et maladies liees a l'aggregation de proteines
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
WO2004042064A3 (fr) Troubles du metabolisme des lipides
WO2003029422A3 (fr) Gene du syndrome de noonan
WO2002004513A3 (fr) Proteines 1 du type region critique 1 du syndrome de down
WO2002097046A3 (fr) Molecules de proteine-2 associees a b7 et utilisation de celles-ci
WO2002072632A3 (fr) Acides nucleiques du gene abcc11 humain, vecteurs contenant lesdits acides nucleiques et leurs utilisations
WO2002101048A3 (fr) Nouveaux polynucleotides et polypeptides du gene ifn$g(a)-7

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP